Neurocrine Biosciences has unveiled an educational initiative, ‘What the C@H?!’, to support patients with congenital adrenal hyperplasia (CAH) and healthcare professionals. The initiative aims to provide a platform for sharing experiences, advice, and educational resources related to CAH. The company anticipates submitting a market application for its CAH drug crinecerfont to the FDA in Q2.